

REMARKS

The Office Action dated March 21, 2006 ("Office Action") has been received and noted. Claims 1-16 and 30 were examined. Claims 1-16 and 30 were rejected. Claims 2, 5-16 are withdrawn. Claims 1, 3-5 and 30 are amended. Support for the amendments can be found in, for example, pages 18 and 19 of the Application. As such, no new matter has been added. Applicants respectfully request reconsideration of the claims in view of the above-amendments and the following remarks.

Applicants would like to express their appreciation to the Examiner for promptly responding to inquiries made by Applicants with respect to the Office Action.

The Examiner states that the Applicants cannot rely upon the foreign priority papers to overcome rejections because the translation of the foreign priority documents has not been made of record in accordance with 37 C.F.R. 1.55. Applicants herein enclose a certified copy of an English language translation of Korean Application No. 10-2002-0003184.

The Examiner rejects the incorporation by reference of GenBank U80456 because protein and nucleic acid sequences that are an essential part of the invention must be disclosed by sequence. In response, Applicants state that Mr. Hanguan Liu of NCBI was contacted and stated that U80456 was first released into the GenBank public database on May 2, 1997 and was updated once on July 8, 1997. Following a comparison of the May 2, 1997 entry and the July 8, 1997 entry, Applicants found that there is no difference between the two sequences. Absent a specific inquiry regarding date of conception, the earliest priority date is January 19, 2002 based on Korean Application No. 10-2002-0003184. Thus, Applicants respectfully submit that GenBank U80456 can be incorporated be referenced. (*See* email correspondence from Jason Lee to Steve De Klerk dated September 13, 2006 and accompanying attachments, attached hereto as Exhibit A). Accordingly, Applicants respectfully request withdrawal of this rejection.

The specification was objected to for the misspelling of "alanine" and "arginine" on page 18, line 13. Appropriate correction has been made.

Claims 1-16 and 30 were objected to due to various informalities. Claims 2 and 6-16 have been withdrawn. Appropriate correction has been made to remaining claims 1, 3-5 and 30.

I. Claims Rejected Under 35 U.S.C. § 101

Claims 1-4 and 30 were rejected under 35 U.S.C. § 101 as being directed to non-statutory subject matter according to the Examiner. Claim 2 is withdrawn. Amended claim 1 reads “[a] peptide comprising SEQ. ID NO.:1 *derived* from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2, wherein the peptide is capable of transducing a biologically active, functional or/and regulatory molecule into prokaryotic cells or eukaryotic cells.” Amended claim 30 reads “[a] method of transducing a peptide into a prokaryotic or eukaryotic cell comprising preparing a peptide construct comprising SEQ. ID NO.:1 *derived* from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2, wherein the peptide includes a biologically active, functional or/and regulatory molecule; and delivering the peptide construct *in vivo* to a subject through administration routes comprising intramuscular, intraperitoneal, intravein, oral, nasal, subcutaneous, intradermal, mucosal and inhalation routes.” The term “derived” recites a limitation of the “hand in man” indicating that the claimed peptide is isolated and/or purified. Dependent claims 3-4 depend on independent claim 1 and therefore include all of its limitations. Applicants respectfully submit that the amendments overcome the Examiner’s rejection.

II. Claims Rejected Under 35 U.S.C. § 112, first paragraph

Claims 1-16 and 30 were rejected under 35 U.S.C. § 112, first paragraph for failing to meet the enablement requirement according to the Examiner. Amended claim 1 reads “[a] peptide comprising SEQ. ID NO.:1 derived from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2, wherein the peptide is capable of transducing a biologically active, functional or/and regulatory molecule into prokaryotic cells or eukaryotic cells.” Amended claim 30 reads “[a] method of transducing a peptide into a prokaryotic or eukaryotic cell comprising preparing a peptide construct comprising SEQ. ID NO.:1 derived from human transcription factor

SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2, wherein the peptide includes a biologically active, functional or/and regulatory molecule; and delivering the peptide construct *in vivo* to a subject through administration routes comprising intramascular, intraperitoneal, intravein, oral, nasal, subcutaneous, intradermal, mucosal and inhalation routes.” The Examiner is on record for stating that the specification is enabling for a peptide comprising the amino acid sequence of SEQ. ID NO.: 1, but has stated that the specification is not enabling for claims which include the term “active fragments”. (Office Action, p. 5, 6) Claims 1, 3-4 and 30 no longer contains the term “active fragments”. Amended claim 5 reads “[a] recombinant expression vector comprising a DNA sequence encoding a peptide comprising SEQ. ID NO.:1 derived from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2.” The Examiner is on record for stating that the specification is enabling for a recombinant expression vector consisting of SEQ. ID NO.:1, but has stated that the specification is not enabling for claims for other limitations in claims 5, 6, 9, 10-11, 14-16. (Office Action, p. 8) Those limitations and/or claims of which the Examiner rejects have been canceled and/or withdrawn. Accordingly, Applicants respectfully submit that claims 1, 3-5 and 30 satisfy the enablement requirement of 35 U.S.C. § 112, first paragraph.

III. Claims Rejected Under 35 U.S.C. § 112, first paragraph

Claims 1-16 and 30 were rejected under 35 U.S.C. § 112, first paragraph for failing to meet the written description requirement according to the Examiner. Amended claim 1 is drawn to a single species, i.e., “[a] peptide comprising SEQ. ID NO.:1 derived from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2.” Amended claim 30 is drawn to a single species, i.e., “[a] method of transducing a peptide into a prokaryotic or eukaryotic cell comprising preparing a peptide construct comprising SEQ. ID NO.:1 derived from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2.” Claims 1, 3-4 and 30 no longer contains the term “active fragments,” of which the Examiner views as being directed to additional species. In addition, amended claim 5 is drawn to a single species, i.e., “[a]

recombinant expression vector comprising SEQ. ID NO.:1 derived from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2.” Limitations and/or claims of which the Examiner rejects as being directed to additional species in claims 5, 6, 9, 10-11, 14-16 have been withdrawn and/or canceled. Accordingly, Applicants respectfully submit that claims 1, 3-5 and 30 satisfy the written description requirement of 35 U.S.C. § 112, first paragraph.

IV. Claims Rejected Under 35 U.S.C. § 112, second paragraph

Claims 1-16 and 30 were rejected under 35 U.S.C. § 112, second paragraph for being indefinite according to the Examiner. Amended claims 1 and 30 claim a specific peptide derived from SEQ. ID NO.:1 comprising an amino acid sequence beginning at the 558th marker of SEQ. ID NO.:1 and ending at the 566th marker of SEQ. ID NO.:1. Dependent claims 3-4 depend on independent claim 1 and therefore include all of its limitations. Amended claim 5 claim a specific recombinant expression vector comprising a DNA sequence encoding a peptide derived from SEQ. ID NO.:1 comprising an amino acid sequence beginning at the 558th marker of SEQ. ID NO.:1 and ending at the 566th marker of SEQ. ID NO.:1. The remaining claims have been withdrawn and/or canceled. Accordingly, Applicants respectfully submit that claims 1, 3-5, and 30 are definite under 35 U.S.C. § 112, second paragraph.

Claim 13 was rejected under 35 U.S.C. § 112, second paragraph as being indefinite. Claim 13 is withdrawn.

Claims 12-14 and 16 were rejected under 35 U.S.C. § 112, second paragraph as being indefinite. Claims 12-14 and 16 are withdrawn.

Claims 4, 8 and 30 were rejected under 35 U.S.C. § 112, second paragraph as omitting essential steps according to the Examiner. Amended claim 4 reads “[t]he peptide of claim 1, wherein the peptide is transduced into the cells of prokaryotes or eukaryotes and administered *in vivo* through administration routes comprising intramuscular, intraperitoneal, intravein, oral, nasal, subcutaneous, intradermal, mucosal and inhaling routes.” Amended claim 30 reads “[a] method of transducing a peptide into a prokaryotic or eukaryotic cell comprising: preparing a

peptide construct comprising SEQ. ID NO.:1 derived from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2, wherein the peptide includes a biologically active, functional or/and regulatory molecule; and delivering the peptide construct *in vivo* to a subject through administration routes comprising intramuscular, intraperitoneal, intravein, oral, nasal, subcutaneous, intradermal, mucosal and inhalation routes.” Thus, it is clear from the claim language that the peptide or peptide construct is delivered via standard delivery routes *in vivo* and transduces a cell once it reaches the cell. Claim 8 is withdrawn. Applicants respectfully submit that the amendments in claims 4 and 30 overcome the Examiner’s rejection.

V. Claims Rejected Under 35 U.S.C. § 102

A.

Claims 1-3 were rejected under 35 U.S.C. § 102(a) as being anticipated by International Publication No. WO 01/57277 A2 to Penn et al. (“*Penn*”). A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference. MPEP 2131. Applicants respectfully submit that each and every element in amended claim 1 and its respective dependent claim is not set forth in the cited references.

Amended claim 1 reads “[a] peptide comprising SEQ. ID NO.:1 derived from human transcription factor SIM2 beginning at the 558th marker of human transcription factor SIM2 and ending at the 566th marker of human transcription factor SIM2, wherein the peptide is capable of transducing a biologically active, functional or/and regulatory molecule into prokaryotic cells or eukaryotic cells.” The nine amino acid residue from the 558th marker of SEQ. ID NO.:1 to the 566th marker of SEQ. ID NO.:1 consists of the sequence AKAARQAAR. By contrast, *Penn* describes genome-derived single exon microarrays useful for verifying the expression of regions of genomic DNA predicted to encode protein. (Penn, Field of Invention) SEQ. ID NO.:31606 of *Penn* includes a 96 amino acid residue which includes the sequence ARAARQAAR, or, more particularly, wherein a lysine is conservatively substituted for arginine when compared to the sequence of the claim 1. (Result 6 of Examiner’s Search Strategy (.rag)) Thus, the cited reference

does not disclose each and every element of independent claim 1. Dependent claim 3 depends from independent claim 1 and therefore includes all of its limitations. Accordingly, Applicants respectfully submit that independent claim 1 and dependent claim 3 are allowable over the cited reference.

B.

Claims 1-9, 11, 14-16 and 30 were rejected under 35 U.S.C. § 102(e) as being anticipated by U.S. Patent No. 6,780,642 to Narayanan (“*Narayanan*”). Applicants respectfully submit that *Narayanan* is not enabled with respect to amended independent claims 1, 5 and 30. *Narayanan* describes methods of detecting cancer in a biological sample by detecting SIM2 nucleic acid or protein in the sample and methods for treating cancer and identifying compounds that modulate SIM2 expression. (*Narayanan*, Abstract) Among the sequences disclosed in *Narayanan* is SEQ. ID NO.:3 which is the native form of the human transcription factor SIM2 gene and contains 667 amino acid residues. (col. 39-43) SEQ. ID NO.:3 is simply a repeat of U80456 of GenBank. (*see* GenBank U80456 available at <http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html>) *Narayanan* is not enabled with respect to SEQ. ID NO.:1 of independent claims 1, 5 and 30 because *Narayanan* does not enable one skilled in the art to make and use the claimed invention. There is no indication that *Narayanan* specifically identifies SEQ. ID NO.:1 or any of its newly discovered capabilities, as discovered by Applicants and claimed in the Application. *Narayanan* does not give any working examples of SEQ. ID NO.:1 and is void in direction or guidance with respect to how to make and use SEQ. ID NO.:1. Moreover, if every newly discovered peptide, protein or nucleic acid sequence encoding a newly discovered peptide or protein derived from a known nucleic acid sequence precluded patentability, then no patent would issue for sequences, including the sequences disclosed in *Narayanan*. Accordingly, Applicants respectfully submit that independent claims 1, 5 and 30 are allowable over the cited reference.

Applicants respectfully remind the Examiner that prior art rejections should ordinarily be confined strictly to the best available art. MPEP 706.02(I). The Examiner rejects the same claims (1-3) under both 35 U.S.C. § 102(a) and 102(e) citing different references. In subsequent any offices action, should one issue, Applicants respectfully request that the Examiner only cite the best reference in any rejection.

CONCLUSION

In view of the foregoing, it is believed that all claims now pending patentably define the subject invention over the prior art of record and are in condition for allowance and such action is earnestly solicited at the earliest possible date.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Date: 9/18/06

Shelley M. Cobos
Shelley M. Cobos, Reg. No. 56,174

12400 Wilshire Boulevard
Seventh Floor
Los Angeles, California 90025
Telephone (310) 207-3800
Facsimile (310) 820-5988

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Melissa Stead 9-18-06
Melissa Stead Date

Shelley Cobos

From: Steve De_Klerk
Sent: Wednesday, September 13, 2006 7:22 PM
To: Shelley Cobos
Cc: Linda Brost
Subject: FW: [Urgent] U.S. National Stage Patent Application 10/501,964
Attachments: U80456_comparison_result.pdf; U80456 (July-8-1997).pdf; U80456 (May-2-1997).pdf

Shelly, please see below and attached. There was also a fax that came in yesterday that we are sending on to you.

From: NAM AND NAM [mailto:nampat@nampat.co.kr]
Sent: Wed 9/13/2006 6:46 PM
To: Steve De_Klerk
Subject: Re: [Urgent] U.S. National Stage Patent Application 10/501,964

Dear Mr. De Klerk :

This is further to our letter of September 13, 2006.

As mentioned in our previous letter, we sent an e-mail to the NCBI and received a reply from Mr. Hanguan Liu of the NCBI as follows:

“Regarding the update history of u80456, the accession number, u80456, was first released into the GenBank public database on May 2, 1997 and was updated once on July 8, 1997.

See the records below:

<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?2062416:NCBI:274571>
[http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?2062416:OLDID:3445559”](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?2062416:OLDID:3445559)

We have compared the sequence released on May 2, 1997 with the sequence updated on July 8, 1997. Consequently, we confirm that there is no difference between the two sequences.

Enclosed herewith please find the information of the above sequences and the comparison result.

Thank you for your continuous cooperation.

Yours sincerely,

Jason LEE
Patent Attorney

Exhibit A

NAM & NAM World Patent & Law Firm.
Kwanghwamoon P.O.Box 58 Seoul Korea
Maekyung Media Center 9th Fl., 30, 1-Ga, Pil-Dong, Jung-Ku, Seoul, Korea
Phone : 82 2 753-5477 Fax : 82 2 753-7315
E-mail : nampat@nampat.co.kr
[Http://www.nampat.co.kr](http://www.nampat.co.kr)

The information contained in this transmission is privileged and confidential information intended only for use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this transmission in error, please immediately reply to the sender that you received this communication and delete it.

Thank you.

Exhibit A

LOCUS HSU80456 3921 bp mRNA linear PRI 02-MAY-
499708-JUL-1997

DEFINITION Human transcription factor SIM2 long form mRNA, complete cds.

ACCESSION U80456

VERSION U80456.1 GI:2062416

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

~~Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;~~

~~Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;~~

~~Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;~~

~~Vertebrata; Eutheria; Primates;~~

Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 3921)

AUTHORS Chrast,R., Scott,H.S., Chen,H., Kudoh,J., Rossier,C., Chen,H., Minoshima,S.,
Shimizu,N.

Minoshima,S.,

Wang,Y., Shimizu,N. and Antonarakis,S.E.

TITLE Cloning of SIM2, ~~a human homologue~~two human homologs of the Drosophila
~~single-minded~~single-minded gene

gene

SIM1 on chromosome 6q and SIM2 on 21q within the Down syndrome

~~JOURNAL~~ Unpublished

chromosomal region

Exhibit A

JOURNAL Genome Res. 7 (6), 615-624 (1997)

PUBMED 9199934

REFERENCE 2 (bases 1 to 3921)

AUTHORS Chrast,R., Kudoh,J., Rossier,C., Chen,H., Minoshima,S., Shimizu,N.
and Antonarakis,S.E.

TITLE Direct Submission

JOURNAL Submitted (29-NOV-1996) Medical Genetics, University of Geneva
Medical School, 1, Rue Michel-Servet, Geneva 1211, Switzerland

FEATURES Location/Qualifiers

source 1..3921

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/chromosome="21"

/map="21q22.2"

CDS 93..2096

/codon_start=1

/product="transcription factor SIM2 long form"

/protein_id="2062417"/protein_id="AAB62396.1"

/db_xref="GI:2062417"

/translation="MKEKSKNAAKTRREKENGFEYELAKLLPLPSAITSQLDKASIIR

Exhibit A

LTTSYLKMRAVFPEGLGDAWGQPSRAGPLDGVAKELGSHLLQTL DGFV FVVASDGKIM

YISETASVHLGLSQVELTGNSIYEYIHPSDHEMTAVLTAHQPLHHHLLQEYEIERSF

FLRMKCVLAKRNAGLTCSGYKVIHCSGYLKIRQYMLDMSLYDSCYQIVGLVAVGQSLP

PSAITEIKLYSNMFMFRASLDLKLIFLDSRVTEVTGYEPQDLIEKTLYHHVHGCDVFH

LRyahllllvkgqvttkyyrllskrggwwvwqsyatvvhnsrssrphcivsvnyvlte

IEYKELQLSLEQVSTAKSQDSWRTALSTSQETRKLVKPKNTKMKTKLRTNPYPQQYS

SFQMDKLECGQLGNWRASPPASAAAPPELQPHSESSDLLYTPSYSLPFSYHYGHFPLD

SHVFSSKKPMLPAKFGQPQGSPCEVARFFLSTLPASGECQWHYANPLVPSSSSPAKNP

PEPPANTARHSLVPSYEAPAAAVRRFGEDTAPPSFPSCGHYREEPALGPAKAARQAAR

DGARLALARAAPECCAPPTPEAPGAPQLPFVLLNYHRVLARRGPLGGAAPAASGLAC

APGGPEAATGALRLRHPSAATSPPGAPLPHYLGASVIITNGR"

ORIGIN

1 actcactata gggctcgagc ggccgcccgg gcaggtgggg ctccgcgggc ctggagcacg

61 gccgggtcta atatgcccg agccgaggcg cgatgaagga gaagtccaag aatgcggcca

121 agaccaggag ggagaaggaa aatggcgagt ttacgagct tgccaagctg ctcccgtgc

181 cgtcggccat cacttcgag ctggacaaag cgtccatcat cgcctcacc acgagctacc

Exhibit A

241 tgaagatgcg cgccgtcttc cccgaagggt taggagacgc gtggggacag ccgagccgcg
301 ccggggcccct ggacggcgtc gccaaaggagc tgggatcgca ctgtctgcag actttggatg
361 gattgtttt tgggtagca tctgatggca aaatcatgta tatatccgag accgcttctg
421 tccatttagc ctatcccag gtggagctca cgggcaacag tatttatgaa tacatccatc
481 cttctgacca cgatgagatg accgctgtcc tcacggccca ccagccgctg caccaccacc
541 tgctccaaga gtagagata gagaggctgt tcttcttcg aatgaaatgt gtcttggcga
601 aaaggaacgc gggcctgacc tgcagcggat acaaggatcat cactgcagt ggctacttga
661 agatcaggca gtatatgctg gacatgtccc tgtacgactc ctgtaccag attgtggggc
721 tggtgccgt gggccagtcg ctgccacca gtgccatcac cgagatcaag ctgtacagta
781 acatgttcat gttcagggcc agccttgacc tgaagctgat attcctggat tccaggggtga
841 ccgaggtgac gggttacgag ccgcaggacc tgatcgagaa gaccctatac catcacgtgc
901 acggctgcga cgtgtccac ctccgctacg cacaccacct cctgttggtg aagggccagg
961 tcaccacca gtactaccgg ctgctgtcca agcggggcgg ctgggtgtgg gtgcagagct
1021 acgccaccgt ggtgcacaac agccgctcgt cccggcccca ctgcatcgtg agtgtcaatt
1081 atgtactcac ggagattgaa tacaaggaac ttcagctgtc cctggagcag gtgtccactg
1141 ccaagtccca ggactcctgg aggaccgcct tgtctacctc acaagaaact aggaaattag
1201 tgaaacccaa aaataccaag atgaagacaa agctgagaac aaacccttac cccccacagc
1261 aatacagctc gttccaaatg gacaaactgg aatgcggcca gtcgggaaac tggagagcca
1321 gtccccctgc aagcgtgct gtcctccag aactgcagcc cactcagaa agcagtgacc
1381 ttctgtacac gccatcctac agcctgccct tctctacca ttacggacac ttccctctgg
1441 actctcacgt cttcagcagc aaaaagccaa tgttccggc caagttcggg cagccccaag
1501 gatccccctg tgaggtagca cgtttttcc tgagcacact gccagccagc ggtgaatgcc

1561 agtggcatta tgccaacccc ctagtgccta gcagctcgtc tccagctaaa aatcctccag
1621 agccaccggc gaacactgct aggcacagcc tgggtccaag ctacgaagcg cccgccgccc
1681 ccgtgcgcag gttcggcgag gacaccgcgc ccccgagctt cccgagctgc ggccactacc
1741 gcgaggagcc cgcgctgggc ccggccaaag ccgcccgcga ggccgcccgg gacggggcgc
1801 ggctggcgct gggccgcgcg gcacccgagt gctgcgcgcc cccgaccccc gagggcccgg
1861 gcgcgccggc gcagctgcc ttcgtgctgc tcaactacca ccgctgctg gcccgccgcg
1921 gaccgctggg gggcgccga cccgccgct ccggcctggc ctgcgctccc ggccggcccc
1981 aggcggcgac cggcgcgctg cggctccggc acccgagccc cgcgccacc tccccccc
2041 gcgcgccct gccgcactac ctgggcgcct cggctatcat caccaacggg aggtgaccg
2101 ctggccgcc gccccaggag cctggacccg gcctccggg gctcggcgcc caccgagccc
2161 ggcaaatgcg cacgacctac attaatatt gcagagacag ctgttgaat tggacccgc
2221 cgccgactg cggattcca ccgcggaggc cccgcgcgcc ggtgccgagg gccgaggagc
2281 gcccgggtcc gggcaggta ccgccgcct ctgtcctgcg agggccggtg cgaccagtt
2341 gctgggggtc tggttcctc acctgaaat cgggcttcac gcgtctgcc ttgtcccaa
2401 cgtccacaa cagtcccgt gggggattga agcggttca ctccgaaat atctccact
2461 ttcaggaggg aaaaccacc ctaccacagt ccgctcttc aagtggacgg cagacctggg
2521 aggggacgcc tgtgtacga gcccttttag atgcttagt gaaggcagaa gtgatattg
2581 taagtccat gaatacaca ctccactgc tttaaagtc attcaagagt ctattatt
2641 ttgttttat ttaaccctt ctcaatata aaaagccaac aaaccaagac taagggggtg
2701 accatgcaat tccatttgt gtctgtgaac ataggtgtc tcccaaata cattaacaag
2761 ctcttactic ccctaacc ctatgaactc ttgataacac caagagtagc acctcagaa
2821 tatattgaat aggcattaaa tgcaaaaata tatatgtagc cagacagtt atgagaatga

2881 cccgtcaag cttcattatt acgtggcaaa atccctctgg cccacacaga tctgtaattc
2941 actaggctcg tgtttgctac aaatagtgt aataaagta aattgcacgt gcaatacggg
3001 acactgtcaa tggactgcac cttgtgaagg aaaaacatgc ttaagggggg gtaatgaaaa
3061 tgaatgacg attttaagca ttctacac agcgagaaaa ctcgtaaga acatgttacg
3121 tgtgaacag gtaaacagaa atccttcat aaagcaccag cagtgttaa aaaatgagct
3181 tccattaatt ttactttt atgggtttg ctaaagatc tcaacatga aaaatcctgt
3241 catggctcg aactgcacaa tgcattgaac cgccgcctt caatttctt cacactatca
3301 acactgcagc atttgctgc ttatcaaaa tggttattt taggaaactt ttccacctt
3361 tctgaatga aagaggttt cacaatgtt taaactcat cgttcaaaa tcaagtgcac
3421 ctacaccaac tgcttcaaa atgtgaactg actttttt tttttttt gccaacctg
3481 tgcacttag tgaggacctg acacaatccc tacagggtgt ctgtcagtg gcctcatggt
3541 aagagtcaca attgcaaat ttaggacctg ggtcatgca gcgaaggggc tggatggtg
3601 gaagggatgt gccgcctct ccacgcactc agctatacct cattcacagc tcctgtgag
3661 tgtgtgcaca ggaaataagc cgagggtatt atttttat gttcatgagt cttgtaatta
3721 aaccgtgatt ctgaaaggt gtaggttga ttactaggag ataccaccga cattttcaa
3781 taaagtactg caaaatgctt ttgtgttac ctgttatta actttgggg ctgtattag
3841 taaaataaaa tcaaggctat cggagcagtt caataacaaa ggttactgt gagaaaaaag
3901 accctatcat agattacaa g

//

Exhibit A

NCBI Nucleotide

My NCBI [Sign In] [Register]

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search Nucleotide for [] Go Clear

Limits Preview/Index History Clipboard Details

Display GenBank Show 5 Send to Hide: ☐ Sequence ☐ Lesser features

Range: from begin to end ☐ Reverse complemented strand Features: ☐ SNP + Refresh

☐ 1: U80456. Reports Human transcripti...[gi:2062416]

Links

Features Sequence

LOCUS HSU80456 3921 bp mRNA linear PRI 08-JUL-1997
DEFINITION Human transcription factor SIM2 long form mRNA, complete cds.
ACCESSION U80456
VERSION U80456.1 GI:2062416
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 3921)
AUTHORS Chrast,R., Scott,H.S., Chen,H., Kudoh,J., Rossier,C., Minoshima,S.,
Wang,Y., Shimizu,N. and Antonarakis,S.E.
TITLE Cloning of two human homologs of the Drosophila single-minded gene
SIM1 on chromosome 6q and SIM2 on 21q within the Down syndrome
chromosomal region
JOURNAL Genome Res. 7 (6), 615-624 (1997)
PUBMED 9199934
REFERENCE 2 (bases 1 to 3921)
AUTHORS Chrast,R., Kudoh,J., Rossier,C., Chen,H., Minoshima,S., Shimizu,N.
and Antonarakis,S.E.
TITLE Direct Submission
JOURNAL Submitted (29-NOV-1996) Medical Genetics, University of Geneva
Medical School, 1, Rue Michel-Servet, Geneva 1211, Switzerland
FEATURES
source Location/Qualifiers
1..3921
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosome="21"
/map="21q22.2"
CDS 93..2096
/codon_start=1
/product="transcription factor SIM2 long form"
/protein_id="AAB62396.1"
/db_xref="GI:2062417"
/translation="MKEKSKNAAKTRREKENGEFYELAKLLPLPSAITSQLDKASIIIR
LTTSYLKMRVFPPEGLGDAWGQPSRAGPLDGVAKELGSHLLQTLDDGFVVFVVASDGKIM
YISETASVHLGLSQVELTGNSIYEIHPDHDDEMTAVLTAHQPLHHLLQYEYIEIERSF
FLRMKCVLAKRNAGLTCSGYKVIHCSGYLKIROYMLDMSLYDSCYQIVGLVAVGQSLP
PSAITEIKLYSNMFMFRASLDLKLIFLDSRVTEVTGYEPQDLIEKTLYHHVHGCDVFH
LRYAHHLLLVKGQVTTKYRLLSKRGWVWVQSYATVVHNSRSPHPCIVSVNYVLTE
IEYKELQLSLEQVSTAKSQDSWRTALSTSQETRKLKVPKNTKMKTKLRTNPYPQQYS
SFQMDKLECGQLGNWRASPPASAAAPPELQPHSESSDLYTPSYSLPFSYHYGHFPLD
SHVFSSKKPMLPAKFGQPQSGPCEVARFFLSTLPASGECQWHYANPLVPSSSSPAKNP
PEPPANTARHSLVPSYEAPAAAVRREGDTAPPSFPSCGHYREEPALGPAKAARQAAR
DGARLALARAPECCAPPTPEAPGAPALPFVLLNHYRVLARRGPLGGAAPASGLAC
APGGPEAATGALRLRHPSAATSPPGAPLPHYLGASVIITNGR"

ORIGIN

1 actcactata gggctcgagc ggccgcccgg gcaggtgggg ctccgcgggc ctggagcacg

Exhibit

A


```

61 gccgggtcta atatgcccgg agccgaggcg cgatgaagga gaagtccaag aatgcggcc
121 agaccaggag ggagaaggaa aatggcgagt ttacgagct tgccaagctg ctcccgtgc
181 cgtcgccat cacttcgcag ctggacaaag cgtccatcat cgcctcacc acgagctacc
241 tgaagatgcg cgccgtcttc cccgaagggt taggagacgc gtggggacag ccgagccgcg
301 ccgggcccc ctgacggcgtc gccaaaggagc tgggatcgca cttgctgcag actttggatg
361 gatttgtttt tgtggtagca tctgatggca aaatcatgta tatatccgag accgcttctg
421 tccatttagg cttatcccag gtggagctca cgggcaacag tatttatgaa tacatccatc
481 cttctgacca cgatgagatg accgctgtcc tcacggccca ccagccgctg caccaccacc
541 tgctccaaga gtatgagata gagaggctcg tctttcttcg aatgaaatgt gtcttggcga
601 aaaggaacgc gggcctgacc tgcagcggat acaaggctcat ccactgcagt ggctacttga
661 agatcaggca gtatatgctg gacatgtccc tgtacgactc ctgctaccag attgtggggc
721 tgggtggcgt gggccagtcg ctgccacca gtgccatcac cgagatcaag ctgtacagta
781 acatgttcat gttcagggcc agccttgacc tgaagctgat attcctggat tccagggtga
841 ccgaggtgac gggttacgag ccgcaggacc tgatcgagaa gacctatac catcacgtgc
901 acggctgcga cgtgttccac ctccgctacg cacaccacct cctgttgggt aagggccagg
961 tcaccacca gtactaccg ctgctgtcca agcggggcgg ctgggtgtgg gtgcagagct
1021 acgccaccgt ggtgcacaac agccgctcgt cccggcccca ctgcatcgtg agtgtcaatt
1081 atgtactcac ggagattgaa tacaaggaa ttcagctgtc cctggagcag gtgtccactg
1141 ccaagtccca ggaactcctg aggaccgcct tgtctacctc acaagaaact aggaaattag
1201 tgaaccacca aaataccaa atgaagacaa agctgagaac aaacccttac ccccacagc
1261 aatacagctc gttccaaatg gacaaactgg aatgcggcc gctcgaaac tggagagcca
1321 gtccccctgc aagcgtgct gtcctccag aactgcagcc ccactcagaa agcagtgacc
1381 ttctgtacac gccatcctac agcctgccct tctcctacca ttacggacac tccctctgg
1441 actctcacgt cttcagcagc aaaaagccaa tgttgccggc caagttcggg cagccccaa
1501 gatccccctg tgaggtggca cgctttttcc tgagcacact gccagccagc ggtgaatgcc
1561 agtggcatta tgccaacccc ctagtgccta gcagctcgtc tccagctaaa aatcctccag
1621 agccaccgac gaacactgct aggcacagcc tgggtgccaag ctacgaagcg cccgcgcggc
1681 ccgtgcgcag gttcggcgag gacaccgcgc ccccgagctt cccgagctgc ggccactacc
1741 gcgaggagcc cgcgctgggc ccggccaaag ccgcccgcga ggccgcccgg gacggggcgc
1801 ggctggcgct ggcccgcgcg gcacccgagt gctgcgcgcc ccgaccccc gagggcccg
1861 gcgcgcgggc gcagctgccc ttcgtgctgc tcaactacca ccgcgtgctg gcccggcgcg
1921 gaccgctggg gggcgccgca cccgcgcct ccggcctggc ctgcgctccc ggcgggccc
1981 aggcggcgac cggcgcgctg cggctccggc acccgagccc cgccgccacc tcccgcgcc
2041 gcgcgccct gccgactac ctggcgccct cggctcatcat caccaacggg aggtgacctg
2101 ctggcgccc gcgccaggag cctggaccgg gcctcccggg gctgcggcgc caccgagccc
2161 ggcaaagtgc cagcacctac attaatatt gcagagacag ctgtttgaat tggacccgc
2221 cgccgacttg cggatttcca ccgcggagg cccgcgcgcc ggtgccgagg gccgaggagc
2281 gcccggtcc gggcaggtga ccgcccgcct ctgtcctgcg agggccgggt cgacccagtt
2341 gctgggggct tggtttctc accttgaaat cgggcttcac gcgtcttgcc ttgtcccaa
2401 cgttcacaa cagtcccgt gggggattga agcggtttca ctccgcaa atcctccact
2461 ttcaggagg aaaaccacc ctaccagat ccgctcttcc aagtggacgg cagactggg
2521 aggggacgcc tgtgtcagca gcccttttag atgcttaggt gaaggcagaa gtgatgattg
2581 taagtcccat gaatacaca ctccactgtc tttaaaagtc attcaagagt ctcatattt
2641 ttgtttttat ttaaccctt cttcaatata aaaagccaac aaaccaagac taagggggtg
2701 accatgcaat tccattttgt gtctgtgaac ataggtgtgc tcccaaata cattaacaag
2761 ctcttacttc cccctaacc ctatgaactc ttgataacac caagagtagc accttcagaa
2821 tatattgaat aggcattaaa tgcaaaaata tatatgtagc cagacagttt atgagaatga
2881 ccctgtcaag cttcattatt acgtggcaaa atcctctgg cccacacaga tctgtaattc
2941 acctggtcgt tgtttgctac aaatagtgtc aataaagtta aattgcacgt gcaatacgg
3001 acactgtcaa tggactgcac cttgtgaagg aaaaacatgc ttaaggggt gtaatgaaa
3061 tgatgtagac attttaagca ttttctacac agcgagaaaa cttcgtaaga acatgttacg
3121 tgtgcaacag gtaaacagaa atcctttcat aaagcaccag cagtgtttta aaaatgagct
3181 tccattaatt ttacttttt atgggttttg cttaaagatc tcaacatgga aaaatcctgt
3241 catggctctg aactgcacaa tgcattgaac cgccgtcctt caattttctt cacactatca
3301 acactgcagc attttgctgc tttatcaaaa tggtttattt taggaaactt tttccacctt
3361 tctgaatgga aagaggtttt cacaatgtt ttaaactcat cgttctaaaa tcaagtgac
3421 ctacaccaac tgctctcaaa atgtgaactg actttttttt ttttttttt gccaacctg
3481 tgtcacttag tgaggacctg acacaatccc tacagggtgt ctgtcagtg ggctcatggt
3541 aagagtcaca atttgcaaat ttaggacctg gggtcatgca gcgaaggggc tggatggtag
3601 gaagggatgt gccgcctct ccacgcactc agctatacct cattcacagc tccttgtgag
3661 tgtgtgcaca ggaaataagc cgagggtatt atttttttat gttcatgagt cttgtaatta
3721 aaccgtgatt cttgaaaggt gtaggtttga ttactaggag ataccaccga catttttcaa
3781 taaagtactg caaaatgctt ttgtgtctac cttgttatta acttttggg ctgtatttag
3841 taaaaataaa tcaaggctat cggagcagtt caataacaaa ggttactgtt gagaaaaaag
3901 accctatcat agatttacaa g

```

//

Exhibit A

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Exhibit A

NCBI Nucleotide

My NCBI [Sign In] [Register]

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search Nucleotide for [] Go Clear

Limits Preview/Index History Clipboard Details

Display GenBank Show 5 Send to Hide ☐ Sequence ☐ Lesser features

Range: from begin to end ☐ Reverse complemented strand Features: ☐ SNP + Refresh

1: U80456. Reports Human transcripti...[gi:2062416]

Links

Features Sequence

LOCUS HSU80456 3921 bp mRNA linear PRI 02-MAY-1997

DEFINITION Human transcription factor SIM2 long form mRNA, complete cds.

ACCESSION U80456

VERSION U80456 GI:2062416

KEYWORDS .

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 3921)

AUTHORS Chrast,R., Kudoh,J., Rossier,C., Chen,H., Minoshima,S., Shimizu,N. and Antonarakis,S.E.

TITLE Cloning of SIM2, a human homologue of the Drosophila single minded gene

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 3921)

AUTHORS Chrast,R., Kudoh,J., Rossier,C., Chen,H., Minoshima,S., Shimizu,N. and Antonarakis,S.E.

TITLE Direct Submission

JOURNAL Submitted (29-NOV-1996) Medical Genetics, University of Geneva Medical School, 1, Rue Michel-Servet, Geneva 1211, Switzerland

FEATURES

source Location/Qualifiers

1..3921

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/chromosome="21"

/map="21q22.2"

CDS 93..2096

/codon_start=1

/product="transcription factor SIM2 long form"

/protein_id="2062417"

/db_xref="GI:2062417"

/translation="MKEKSKNAAKTRREKENGFEYELAKLLPLPSAITSQLDKASIIIR
LTTSYLKMRAVFPEGLGDAWGQPSRAGPLDGVAKELGSHLLQTLDFVVFVVASDGKIM
YISETASVHLGLSQVELTGNSIYEIHPSDHDEMTAVLTAHQPLHHLLQYEIERISF
FLRMKCVLAKRNAGLTCSGYKVIHCSGYLKIRQYMLDMSLYDSCYQIVGLVAVGQSLP
PSAITEIKLYSNMFMFRASLDLKLIFLDSRVTEVTGYEQDLIEKTLYHHVHGCDVFH
LRYAHHLLLVKGQVTTKYRLLSKRGWVWVQSYATVVHNSRRSPHCIVSVNYVLTE
IEYKELQLSLEQVSTAKSQDSWR TALSTSQETRKLVPKNTKMKTKLRTPYPQQYS
SFQMDKLECGQLGNWRASPPASAAAPPELQPHSESSDLLYTPSYSLPFSYHYGHFPLD
SHVFSSKKPMPLPAKFGQPQSGPCEVARFFLSTLPASGECQWHYANPLVPSSSSPAKNP
PEPPANTARHSLVPSYEAPAAAVRRFGEDTAPPSFPCGHYREEPALGPAAKARQAAR
DGARLALARAAPCECAPPTPEAPGAPQLPFVLLNYHRVLIARRGPLGGAAPASGLAC
APGPEAATGALRLRHPSAATSPPGAPLPHYLGASVIITNGR"

ORIGIN

1 actcactata gggctcgagc ggcgcccgg gcaggtgggg ctccgcgggc ctggagcacg

61 gccgggtcta atatgcccg agccgagggc cgatgaagga gaagtccaag aatgcggcca

121 agaccaggag ggagaaggaa aatggcgagt ttacagagct tgccaagctg ctcccgtcgc

181 cgtcggccat cacttcgcag ctggacaaag cgtccatcat ccgctcacc acgagctacc

Exhibit A

```

241 tgaagatgcg cgccgtcttc cccgaaggtt taggagacgc gtggggacag cccgagccgcg
301 ccggggccctt ggacggcgtc gccaaaggagc tgggatcgca cttgctgcag actttggatg
361 gatttgtttt tgtggtagca totgatggca aaatcatgta tatatccgag accgcttctg
421 tccattttagg cttatcccag gtggagctca cgggcaacag tatttatgaa tacatccatc
481 cttctgacca cgatgagatg accgctgtcc tcacggccca ccagccgctg caccaccacc
541 tgctccaaga gtatgagata gagaggctcg tctttcttcg aatgaaatgt gtcttggcga
601 aaaggaacgc gggcctgacc tgcagcggat acaaggatcat ccaactgcagt ggtactttga
661 agatcaggca gtatatgtcg gacatgtccc tgtacgactc ctgctaccag attgtggggc
721 tgggtggcgt gggccagtcg ctgccacca gtgccatcac cgagatcaag ctgtacagta
781 acatgttcat gttcagggcc agccttgacc tgaagctgat attcctggat tccagggtga
841 ccgaggtgac ggggttacgag ccgcaggacc tgcacgagaa gacctatac catcacgtgc
901 acggtgcga cgtgttccac ctccgctacg cacaccacct cctgttgggtg aaggggccagg
961 tcaccaccaaa gtactaccgg ctgctgtcca agcggggcgg ctgggtgtgg gtgcagagct
1021 acgccaccgt ggtgcacaa agcgcctcgt cccggcccca ctgcatcgtg agtgtcaatt
1081 atgtactcac ggagattgaa tacaaggaac ttcagctgtc cctggagcag gtgtccactg
1141 ccaagtccca ggactcctgg aggaccgcct tgtctacctc acaagaaact aggaaattag
1201 tgaaacccaa aaataccaag atgaagacaa agctgagaac aaacccttac cccccacagc
1261 aatacagctc gttccaaatg gacaaactgg aatgcggcca gctcggaaac tggagagcca
1321 gtccccctgc aagcgtcgt gctcctccag aactgcagcc ccactcagaa agcagtgacc
1381 ttctgtacac gccatcctac agcctgcctt tctcctacca ttacggacac ttccctctgg
1441 actctcacgt cttcagcagc aaaaagccaa tgttgccggc caagttcggg cagccccaag
1501 gatccccttg tgaggtggca cgctttttcc tgagcacact gccagccagc ggtgaatgcc
1561 agtggcatta tgccaacccc ctagtgccta gcagctcgtc tccagctaaa aatcctccag
1621 agccaccggc gaacactgct aggcacagcc tggtgccaag ctacgaagcg cccgcgcgcg
1681 ccgtgcgcag gttcggcgag gacaccgcgc ccccgagctt cccgagctgc ggccactacc
1741 gcgaggagcc cgcgctgggc ccggcccaag ccgcccgcga ggccgcgcgc gacggggcgc
1801 ggctggcgct gggccgcgcg gcacccaggt gctgcgcgcc cccgacccc gagggccgcg
1861 gcgcgcgcgc gcagctgccc ttcgtgtctc tcaactacca ccgctgtctg gcccggcgcg
1921 gaccgctggg gggcgccgca cccgcgcct ccggcctggc ctgcgctccc ggcgcccccg
1981 aggcgcgcgc cggcgcgctg cggctccggc acccgagccc cgcgcgccac tcccgcgcgc
2041 gcgcgcgcct gccgcactac ctgggcgcct cggctcatcat caccaacggg aggtgacccg
2101 ctggccgcgc gcgccaggag cctggaccgc gcctcccggg gctgcggcgc caccgagccc
2161 ggcaaatgcg cagacctac attaatatat gcagagacag ctggttgaat tggacccgcg
2221 gcgcgacttg cggatttcca ccgcggaggg cgtgcccagg ggtgccgagg gccgaggagc
2281 gcccgggtcc gggcagggtg ccgcgcgcct ctgtcctgcg agggccgggtg cgacccagtt
2341 gctgggggct tggtttcttc accttgaaat cgggcttcac gcgtcttgcc ttgtcccaa
2401 cgttccacaa cagtcccgcg gggggattga agcgggttca ctccgcaaat atcctccact
2461 ttcaggaggg aaaacccacc ctaccacagt ccgctcttcc aagtggacgg cagacctggg
2521 aggggacgcc tgtgtcacga gcccttttag atgcttaggt gaaggcagaa gtgatgattg
2581 taagtcccat gaatacacia ctccactgtc tttaaaagtc attcaagagt ctcatatttt
2641 ttgtttttat ttaacccttt cttcaatata aaaagccaac aaaccaagac taaggggggtg
2701 accatgcaat tccattttgt gtctgtgaac ataggtgtgc ttcccaaata cattaacaag
2761 ctcttacttc cccctaacc cttatgaact ttgataacac caagagtagc accttcagaa
2821 tatattgaat aggcattaaa tgcaaaaata tatatgtagc cagacagttt atgagaatga
2881 ccctgtcaag cttcattatt acgtggcaaa atccctctgg ccacacaga tctgtaattc
2941 actaggctcg tgtttgtcac aaatagtgtc aataaaagta aattgcacgt gcaatacggg
3001 aactgtcaa tggactgcac cttgtgaagg aaaaacatgc ttaagggggg ttaatgaaaa
3061 tgatgtagac attttaagca tttctacac agcgagaaaa ctctgtaaga acatgttacg
3121 tgtgcaacag gtaaacagaa atcctttcat aaagcaccag cagtgtttaa aaaatgagct
3181 tccattaatt tttacttttt atgggttttg cttaaagatc tcaacatgga aaaatcctgt
3241 catggctctg aactgcacaa tgcattgaac cgccgtcctt caattttctt cactatca
3301 aactgcagc attttgctgc tttatcaaaa tgggtttatt taggaaactt tttccacctt
3361 tctgaatgga aagaggtttt cacaaatgtt taaactcat cgttctaaaa tcaagtgcac
3421 ctacaccaac tgctctcaaa atgtgaactc actttttttt tttttttttt gccaacctgt
3481 tgtcacttag tgaggacctg accaatccc tacagggtgt ctgtcagtg gctcatggtg
3541 aagagtcaca atttgcaaat ttaggacctg gggcatgca gcgaaggggc tggatggtag
3601 gaagggatgt gccgcctct ccacgcactc agctatacct cattcacagc tccttgtgag
3661 tgtgtgcaca ggaaataagc cgagggtatt atttttttat gttcatgagt cttgtaatta
3721 aaccgtgatt cttgaaaggt gtaggtttga ttactaggag ataccaccga catttttcaa
3781 taaagtactg caaaatgctt ttgtgtctac cttgttatta acttttgggg ctgtatttag
3841 taaaaataaa tcaaggctat cggagcagtt caataacaaa ggttactgtt gagaaaaaag
3901 accctatcat agattttacaa g

```

//